Treatment of at-level spinal cord injury pain with botulinum toxin A
Audrey Chun,Isaiah Levy,Ajax Yang,Andrew Delgado,Chung-Ying Tsai,Eric Leung,Kristell Taylor,Stephanie Kolakowsky-Hayner,Vincent Huang,Miguel Escalon,Thomas N. Bryce
DOI: https://doi.org/10.1038/s41394-019-0221-9
2019-09-18
Spinal Cord Series and Cases
Abstract:Study designRandomized, double-blinded, placebo-controlled, cross-over study.ObjectiveTo explore whether botulinum toxin A (BoNTA) could be effective for treating at-level spinal cord injury (SCI) pain.SettingOutpatient SCI clinic, New York, USA.MethodsParticipants were randomized to receive subcutaneous injections of either placebo or BoNTA with follow-up (office visit, telephone, or e-mail) at 2, 4, 8, and 12 weeks to assess the magnitude of pain relief post injection. Crossover of participants was then performed. Those who received placebo received BoNTA, and vice versa, with follow-up at 2, 4, 8, and 12 weeks.ResultsEight participants completed at least one of the two crossover study arms. Four completed both arms. The median age of the eight participants was 45 years (range 32–61 years) and 75% were male. All had traumatic, T1-L3 level, complete SCI. Although our data did not meet statistical significance, we noted a higher proportion of participants reporting a marked change in average pain intensity from baseline to 8 and 12 weeks post-BoNTA vs. post-placebo (33% vs. 0%). At 2 and 4 weeks post-BoNTA, almost all participants reported some degree of reduced pain, while the same was not seen post-placebo (83% vs. 0%).ConclusionThe subcutaneous injection of BoNTA may be a feasible approach for the control of at-level SCI pain and is worthy of further study.SponsorshipThe onabotulinumtoxinA (BOTOX) used in this study was provided by Allergan (Irvine, CA).